Skip to main content
Premium Trial:

Request an Annual Quote

Clontech Becomes Exclusive Supplier of Ludwig Cancer Research's Smart-seq Technology

NEW YORK (GenomeWeb) – Clontech Laboratories has signed an agreement with Ludwig Cancer Research to become the exclusive supplier of the Smart-seq2 method for single-cell RNA sequencing, the company said today.

The method was developed in the laboratory of Rickard Sandberg at the Ludwig Institute for Cancer Research in Stockholm and the Karolinska Institute and published by his group in 2013. It allows researchers to sequence RNA from single cells with increased yield and length of cDNA libraries.

Smart-seq2 is itself an improvement of the original Smart-seq method, which was developed by Illumina and commercialized by Clontech.

Clontech, a wholly-owned subsidiary of Takara Bio of Japan, said it continues to develop related technologies, such as the recently launched DNA Smart kit for ChIP-seq library construction from low-input double-stranded and single-stranded DNA templates.